This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Gilead Sciences Acquires Tubulis
Business acquisition

Gilead Sciences Acquires Tubulis

Analysis based on 6 articles · First reported Apr 07, 2026 · Last updated Apr 16, 2026

Sentiment
70
Attention
6
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The acquisition of Tubulis by Gilead Sciences is expected to positively impact Gilead Sciences' stock price due to the expansion of its oncology pipeline and enhanced ADC capabilities. This deal also signals increased M&A activity in the biotechnology sector, potentially driving valuations for other clinical-stage companies.

Biotechnology Pharmaceuticals Oncology
Event Summary

Gilead Sciences has entered into a definitive agreement to acquire Tubulis, a Germany-based clinical-stage biotechnology company, for $3.15 billion in upfront cash and up to $1.85 billion in contingent milestone payments. This acquisition aims to significantly expand Gilead Sciences' oncology pipeline, particularly in antibody-drug conjugates (ADCs), by adding Tubulis' next-generation assets like TUB-040 and TUB-030. Following the transaction, expected to close in the second quarter of 2026, Tubulis will operate as a dedicated ADC research organization within Gilead Sciences, with its Munich site becoming a hub for ADC innovation. Daniel O Day, Chairman and CEO of Gilead Sciences, emphasized the strategic importance of this deal, building on a two-year collaboration between the companies. The transaction will be financed through a combination of cash on hand and senior unsecured notes.

Entities Involved
priv
Tubulis
Tubulis is being acquired by Gilead Sciences for $3.15 billion upfront and up to $1.85 billion in milestone payments. It will operate as a dedicated ADC research organization within Gilead Sciences, serving as a hub for innovation.
Importance 100.0 Sentiment 90.0
per
Daniel O Day
Daniel O Day, Chairman and CEO of Gilead Sciences, commented on the acquisition, highlighting its significance for Gilead Sciences' oncology progress and the strong conviction in Tubulis' programs.
Importance 50.0 Sentiment 60.0
priv
Allen & Company
Allen & Company served as a financial advisor for Gilead Sciences in this acquisition.
Importance 10.0 Sentiment 0.0
priv
Centerview Partners
Centerview Partners served as a financial advisor for Gilead Sciences in this acquisition.
Importance 10.0 Sentiment 0.0
subs
JPMorgan Chase — JPMorgan Chase
JPMorgan Chase — JPMorgan Chase acted as the exclusive financial advisor for Tubulis in this acquisition.
Importance 10.0 Sentiment 0.0
stock
Gilead Sciences
Importance 0.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.